Form 4: Trevi Therapeutics Director David P. Meeker Executes Stock Option and Sells Shares

Director David P. Meeker exercised stock options and sold shares of Trevi Therapeutics on August 27, 2024.

Summary

• On August 27, 2024, David P. Meeker, a director of Trevi Therapeutics, Inc., exercised a stock option to acquire 4,555 shares of common stock at a price of $1.43 per share.
• Simultaneously, Meeker sold 4,555 shares of common stock at a weighted average price of $2.9314, with individual sales ranging from $2.9100 to $2.9500.
• Following these transactions, Meeker directly owns 352,489 shares of Trevi Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like directors and officers, trade their company's stock. These filings provide transparency into insider transactions, which can be closely watched by investors for signals about a company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common metric used to assess company health and management confidence.
• Comparing Meeker's transactions to those of other directors in similar pharmaceutical companies could provide insights into whether this activity is typical or unusual.
• For example, if other directors in peer companies like Galera Therapeutics or Cara Therapeutics are also selling shares, it might indicate broader industry trends or concerns.

Stakeholder Impact

• Shareholders may interpret the insider sale as a lack of confidence, although it could also be for personal financial reasons.
• The transaction itself has a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates